欧盟委员会正式批准了复宏汉霖与Organon公司联合开发的Poherdy®（帕妥珠单抗），该药物成为欧洲地区首个获得上市许可的Perjeta（帕妥珠单抗）生物类似药。这一批准标志着两家公司在生物制药领域取得重要突破，将为欧洲市场提供更多治疗选择。
欧盟委员会正式批准了复宏汉霖与Organon公司联合开发的Poherdy®（帕妥珠单抗），该药物成为欧洲地区首个获得上市许可的Perjeta（帕妥珠单抗）生物类似药。这一批准标志着两家公司在生物制药领域取得重要突破，将为欧洲市场提供更多治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.